سعر ماكساميكا 250 مجم/مل فيال 2023

Amikacin (as sulfate) 250 mg/mL solution for intramuscular or intravenous injection, 1 vial (volume not stated) (Chemipharm, Egypt); an aminoglycoside antibiotic for serious Gram-negative infections.

• Short-term treatment of serious infections due to susceptible Gram-negative bacteria: bacterial septicaemia (including neonatal sepsis); serious respiratory tract, bone and joint, CNS (including meningitis) and skin and soft-tissue infections; intra-abdominal infections (including peritonitis); burns and postoperative infectionsPopulation: Adults, children and neonatesDailyMed (U.S. National Library of Medicine)
• Serious complicated and recurrent urinary tract infections due to susceptible organismsPopulation: Adults and childrenDailyMed (U.S. National Library of Medicine)
• Known or suspected staphylococcal infections under certain conditions (e.g. severe infections where the organism may be Gram-negative or staphylococcal; patients allergic to other antibiotics; mixed infections)Population: Adults and childrenDailyMed (U.S. National Library of Medicine)

• Ototoxicity (hearing loss, loss of balance), neuromuscular blockade (acute muscular paralysis, apnoea) and nephrotoxicity (raised creatinine, albuminuria, casts, azotaemia, oliguria; acute renal failure postmarketing). Rarely: rash, drug fever, headache, paraesthesia, tremor, nausea and vomiting, eosinophilia, arthralgia, anaemia, hypotension, hypomagnesaemia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to amikacin; hypersensitivity or serious toxic reactions to other aminoglycosides may contraindicate use because of cross-sensitivity.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: potential ototoxicity (vestibular and permanent bilateral auditory) and nephrotoxicity; risk is greater with renal impairment, higher doses or prolonged therapy; keep patients under close clinical observation.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: neuromuscular blockade and respiratory paralysis, especially with anaesthetics, neuromuscular blocking agents or massive citrate-anticoagulated blood transfusions.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: avoid concurrent or sequential use of other neurotoxic or nephrotoxic drugs (e.g. bacitracin, cisplatin, amphotericin B, polymyxin B, colistin, vancomycin, other aminoglycosides) and potent diuretics (ethacrynic acid, furosemide).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Potent diuretics (ethacrynic acid, furosemide)Avoid concurrent use: diuretics may cause ototoxicity and, given IV, may enhance aminoglycoside toxicity.DailyMed (U.S. National Library of Medicine)
• Other neurotoxic/nephrotoxic drugs (e.g. cisplatin, amphotericin B, vancomycin, polymyxins, other aminoglycosides, cephalosporins)Avoid concurrent or sequential use because of additive nephrotoxicity, ototoxicity and neurotoxicity.DailyMed (U.S. National Library of Medicine)
• Anaesthetics and neuromuscular blocking agentsRisk of neuromuscular blockade and respiratory paralysis.DailyMed (U.S. National Library of Medicine)

• It is not known whether amikacin is excreted in human milk; decide whether to discontinue nursing or the drug, considering its importance to the mother.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Amikacin: Binds to the bacterial (prokaryotic) ribosome and inhibits protein synthesis; bactericidal in vitro against Gram-positive and Gram-negative bacteria (US label).